Monday, 01 March 2021

IIT Delhi to develop home-based COVID-19 testing kit

18 August 2020 | News

IIT Delhi and Wells Fargo recently signed a Memorandum of Understanding (MoU) for the development of a peptide-based ELISA test for the detection of COVID-19 antibodies

Image credit- shutterstock.com

Image credit- shutterstock.com

US based Wells Fargo International Solutions Private Limited through their philanthropic partner, United Way of Bengaluru (UWBe), has joined hands with IIT Delhi in this fight against coronavirus.

IIT Delhi and Wells Fargo recently signed a Memorandum of Understanding (MoU) for the development of a peptide-based ELISA test for the detection of COVID-19 antibodies.
 
ELISA, short for serological enzyme-linked immunosorbent assay, determines whether a person possesses antibodies for COVID-19 in the blood. The test results can help the medical fraternity fight the disease in many ways; a significant way would be the identification of individuals with antibodies who can donate their blood as part of an experimental treatment of infected patients.
 
This project- a collaboration between IIT Delhi and National Chemical Laboratory (NCL), Pune - has the potential of making a meaningful difference to this situation by enabling affordable, home-based testing. 
 
This research will utilise the microplate-based enzyme immune-assay technique. The choice of antigen will be a peptide that has been computationally identified. Structural analysis of the available complex will be performed to design a novel peptide that has a complementary property with spike protein of COVID-19.
 
A set of peptides will be designed using a combination approach to test their binding. From the sequences of the variable regions of the Heavy and Light chain including the novel designed peptide, cloning of the mAb fragment (CV-Fab) will be performed. CV-Fab will be produced from which ELISA based testing kits will created.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls